• What High-Yield Rabbit Pharming Evidence Shows

  2026-11-13

  A targeted rabbit milk-protein locus produced a striking reporter concentration, but the evidence comes from a small, non-head-to-head comparison and does not yet establish general performance for therapeutic proteins.

• How Amantadine-d6 Supports PK Analysis

  2026-11-12

  Amantadine-d6 is best understood as an analytical reference for distinguishing and quantifying amantadine in mass-spectrometric studies. Its deuterium label changes the measured mass while preserving a closely related chemical structure, helping connect a biological sample to a more reliable concentration estimate without directly measuring antiviral, ion-channel, or anticancer activity.

• What Makes mRNA-LNP Translation Robust?

  2026-11-12

  A literature-focused analysis of how lipid chemistry, manufacturing controls, analytical characterization, and comparability planning shape the translation of mRNA lipid nanoparticles from promising formulations into clinically credible products.

• A Targeted Promoter Strategy for Rabbit Pharming

  2026-11-11

  A 2025 study reports that placing a reporter transgene at the endogenous CSN2 milk-protein locus produced 15–20 g/L tdTomato in milk from two homozygous rabbits. The result supports a promising locus-directed strategy, while comparisons with conventional pharming remain contextual rather than head-to-head and do not yet establish equivalent performance for therapeutic proteins.

• Why CSN2 Targeting Raises Rabbit Pharming Yield

  2026-11-11

  A 2025 study used targeted insertion at the endogenous CSN2 milk-protein locus to create a heritable rabbit line expressing tdTomato at 15–20 g/L in milk. The result supports a promising proof of concept, while its translation to therapeutic proteins, manufacturing output, and broader rabbit populations remains unresolved.

• How a CSN2 Knock-In Raised Rabbit Pharming Yield

  2026-11-10

  A 2025 study tested whether placing a recombinant reporter gene at the rabbit CSN2 milk-protein locus could improve expression in milk. The resulting line produced 15–20 g/L tdTomato in milk from two homozygous females, but the finding remains an early proof of concept because it concerns a reporter protein, a small number of animals, and comparisons drawn largely from non-equivalent prior studies.

• CSN2 Targeting and High-Yield Rabbit Pharming

  2026-11-10

  A 2025 study reported that placing a fluorescent reporter at the endogenous CSN2 milk-protein locus produced 15–20 g/L in milk from two homozygous rabbits. The result supports a promising locus-based strategy, while leaving important questions about therapeutic proteins, product quality, biological replication, and cross-study comparability.

• When Context Changes What a Yield Means

  2026-11-09

  A reported protein yield is not an isolated property of a construct or material. In rabbit pharming, the meaning of a 15–20 g/L result depends on the milk-specific promoter, genomic locus, zygosity, reporter protein, comparator lines, and the distinction between expression and a clinically usable product.

• Why Milk-Protein Loci Raise Pharming Yield

  2026-11-09

  A targeted insertion into the rabbit CSN2 locus produced unusually high reporter-protein concentrations in milk. The result supports a mechanistic role for endogenous milk-protein regulation, while leaving important questions about protein-specific behavior, biological activity, production consistency, and generalizability.

• Targeted Expression in Rabbit Pharming

  2026-11-08

  A 2025 study tested whether placing a reporter gene under the control of the rabbit CSN2 milk-protein locus could overcome the variable expression associated with conventional transgenic pharming. The reported 15–20 g/L milk concentration in two homozygous animals is a striking proof of concept, but the result remains an indirect comparison based on a reporter protein and a small animal set.

• When Context Changes a Yield Result

  2026-11-07

  A 15–20 g/L reporter concentration in rabbit milk is best interpreted as a locus-and-promoter proof of concept, not as a universal production benchmark. The result becomes more informative when its reporter, genotype, comparator, measurement, and relationship to HEPES buffering contexts are kept distinct.

• How Endogenous Promoters Reshape Rabbit Pharming

  2026-11-06

  A targeted CSN2 knock-in strategy produced unusually high reporter-protein concentrations in rabbit milk, while leaving important questions about generalizability, product quality, and causal mechanism unresolved.

• Why the CSN2 Locus Raises Rabbit Pharming Yield

  2026-11-06

  A targeted rabbit line achieved substantially higher reporter-protein levels than historical pharming lines by coupling transgene expression to the endogenous CSN2 milk-protein regulatory context. The result supports locus-aware design as a promising mechanism, while the use of a reporter protein, a small number of homozygous animals, and literature-based rather than matched comparisons limits how broadly the finding can be applied.

• Panoramic Mapping of Infarct Structure and Function

  2026-11-05

  A proof-of-concept study combined panoramic hyperspectral imaging with optical mapping to relate epicardial tissue composition to cardiac electrical activity in infarcted rat hearts. The approach revealed spatially distinct infarct and border-zone signals and linked them to exploratory differences in action-potential behavior.

• Why Rabbit Milk Yield Rose in a Targeted Knock-In

  2026-11-05

  A 2025 study reported markedly higher recombinant-protein concentrations in rabbit milk after placing a fluorescent reporter at the endogenous CSN2 milk-protein locus. The finding supports a promising expression strategy, but its strength is limited by the small number of high-yield animals, the use of a reporter rather than a therapeutic protein, and comparisons drawn mainly from heterogeneous historical studies.

8680 records 1/579 page Next 12345 下5页 Last page